

#36

Principal Investigator Peter J. Snyder

Study Title: A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands

Purpose:

To test the safety and efficacy of paltusotine, an oral medication, for the treatment of acromegaly.

Brief Description

Paltusotine will be taken orally once a day, and its effect on the clinical manifestations and blood levels of IGF-1 will be evaluated every four weeks. The initial study lasts 48 weeks, and an optional extension lasts 96 weeks.

Eligibility

Men and women who are 18-80 years of age who have been diagnosed as having acromegaly and are currently be being treated with long-acting somatostatin receptor ligands (lanreotide or octreotide).

Compensation (if applicable)

Subjects will receive compensation to cover travel and parking

Which section would you like the trial listed under? Pituitary Center Trials

Name Eileen Markmann

Phone (215) 898-5664

Email: markmann@penmedicine.upenn.edu